title: Different serial changes in the neointimal condition of sirolimus-eluting stents and paclitaxel-eluting stents: an optical coherence tomographic study.
abstract: OBJECTIVE
  Detailed long-term changes of the neointima in sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) are still unclear.
  
  
  RESULTS
  We consecutively enrolled 14 patients (18 SES) and 12 patients (13 PES) who underwent optical coherence tomography (OCT) serially at eight months and 18 months after stent implantation. For 18 SES and 13 PES, OCT was used to visualise 2,486 and 1,361 stent struts at the eight-month and 2,199 and 1,309 stent struts at the 18-month follow-up, respectively. The OCT parameters, including incidence of uncovered and malapposed struts (uncovered and malapposed percentage), average neointimal hyperplasia thickness (NIH thickness) and %NIH volume obstruction, which was defined as ([mean NIH area*stent length]/[mean stent area*stent length])100, and qualitative analysis of the neointima were compared between SES and PES and also compared between the eight- and 18-month follow-up for SES and PES, respectively. The uncovered and malapposed percentage was significantly higher in SES than PES at the eight- and 18-month follow-up, and the NIH thickness and %NIH volume obstruction were lower in SES than PES at both follow-ups. The uncovered and malapposed percentage decreased in both SES and PES between the eight- and 18-month follow-up. Percent NIH volume obstruction and NIH thickness in SES significantly increased from the eight- to 18-month follow-up; however, those parameters significantly decreased in PES. The incidence of high signal with peri-strut low-intensity areas increased in SES but decreased in PES from the eight- to 18-month follow-up.
  
  
  CONCLUSIONS
  Uncovered and malapposed struts were reduced in both SES and PES, while the neointimal hyperplasia and qualitative changes showed different patterns.
authors.affiliation: Division of Cardiology, Osaka Rosai Hospital, Osaka, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Nakamura
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Lee
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Masayuki
authors.initials: M
authors.lastname: Taniike
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Makino
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Kato
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Egami
authors.forename: Ryu
authors.initials: R
authors.lastname: Shutta
authors.forename: Jun
authors.initials: J
authors.lastname: Tanouchi
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Yamada
authors.forename: Masahiko
authors.initials: M
authors.lastname: Hara
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Sakata
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Hamasaki
authors.forename: Masami
authors.initials: M
authors.lastname: Nishino
mesh_terms: D054058:Acute Coronary Syndrome / Q000209:etiology / Q000601:surgery*; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D023903:Coronary Restenosis / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000473:pathology / Q000601:surgery; D003331:Coronary Vessels / Q000473:pathology*; D018450:Disease Progression; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058426:Neointima / Q000473:pathology*; D017239:Paclitaxel / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention; D012189:Retrospective Studies; D020123:Sirolimus / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence
chemical_list: D000970:Antineoplastic Agents; D017239:Paclitaxel; D020123:Sirolimus